Dorzolamide; Timolol

What it is

This is a single eye-drop bottle containing two pressure-lowering drugs: dorzolamide hydrochloride 2%, a sulfonamide carbonic anhydrase inhibitor, and timolol maleate 0.5%, a non-selective beta-blocker. Dorzolamide inhibits human carbonic anhydrase II in the ciliary processes; timolol is a beta-1 and beta-2 adrenergic receptor blocking agent with no significant intrinsic sympathomimetic activity. It is sold both preserved with benzalkonium chloride and preservative-free. Although applied to the eye surface, both drugs reach the bloodstream.

What the research says

The evidence that this drop lowers intraocular pressure is strong and consistent; the evidence that lowering pressure with these particular drugs preserves vision is weaker and partly negative. A 114-trial network meta-analysis puts timolol's own 3-month effect at about 3.7 mmHg and dorzolamide's at about 2.5 mmHg, both below the prostaglandin analogues. Randomised comparison shows the fixed combination is about as effective as taking the two drops separately, and the label itself states the combination is slightly weaker than concomitant dosing. The large placebo-controlled trial of dorzolamide in ocular hypertension (EGPS) did not show fewer people progressing to glaucoma than placebo. The commonest problems are bitter taste and ocular stinging, in up to 30% of people, and because timolol is absorbed systemically there are documented cases and a pharmacoepidemiological signal for bradycardia.

Evidence grade: Well established.

How it works

Drug class: Fixed-dose topical ophthalmic combination of a carbonic anhydrase inhibitor (dorzolamide) and a non-selective beta-1/beta-2 adrenergic receptor blocker (timolol)

Both drugs in the drop lower pressure inside the eye by cutting the rate at which the eye makes aqueous humour, the clear fluid that fills the front of the eye. Dorzolamide blocks carbonic anhydrase II in the ciliary body, slowing bicarbonate formation and the sodium and water movement that follows it. Timolol blocks beta-adrenergic receptors in the same tissue. Neither drug acts on the optic nerve itself; the only thing they change is the pressure, which is a risk factor for nerve damage rather than the damage itself. (Source 1)

What it is used for

• Both components lower intraocular pressure against placebo, and the fixed combination performs about as well as its two components given separately and about 1 mmHg less well than concomitant dosing. The size of the effect is modest compared with prostaglandin analogues. Evidence: established. (Source 2)
• The label only claims pressure reduction, not preserved vision. OHTS, using whatever topical drug reached target, cut 5-year conversion to glaucoma from 9.5% to 4.4%. EGPS, which randomised dorzolamide against its own vehicle, found no significant difference in conversion, in part because the placebo group's pressure also fell. Evidence: disputed. (Source 3)
• A meta-analysis of four small randomised trials (98 patients, 150 eyes) found adding topical timolol-dorzolamide or dorzolamide to intravitreal bevacizumab gave similar visual acuity and similar macular thickness change, with a larger fall in intraocular pressure. The trials are small and short. Evidence: limited. (Source 4)
• Evidence is retrospective and uncontrolled. In a single-centre series of 40 responders, oedema came back in 15.6% by 1 year and 48.7% by 5 years despite continued dorzolamide, so even among responders the effect is not durable. Evidence: limited. (Source 5)

Interactions

• Oral carbonic anhydrase inhibitors (for example acetazolamide, methazolamide) (label): The eye drop already delivers enough dorzolamide to the bloodstream to inhibit carbonic anhydrase, so adding a tablet of the same class can produce additive systemic effects. The label advises against combining them. (Source 6)
• High-dose salicylate, including high-dose aspirin (label): Carbonic anhydrase inhibition can shift acid-base and electrolyte balance, which has been linked to salicylate toxicity with the oral drugs of this class. The label says this was not seen in the dorzolamide eye-drop trials but should still be considered. (Source 6)
• Oral beta-blockers (for example atenolol, metoprolol, propranolol) (label): Timolol from the drop adds to beta-blockade already present from a tablet, so heart rate and airway effects can stack. (Source 6)
• Calcium channel blockers (verapamil, diltiazem and others) (label): Combining a beta-blocker with a calcium antagonist can slow conduction through the heart and drop blood pressure. (Source 6)
• CYP2D6 inhibitors, including quinidine and SSRI antidepressants (label): These drugs slow timolol's breakdown, so more of it circulates and systemic beta-blockade is stronger. Reported effects include a slower heart rate and depression. (Source 7)
• Catecholamine-depleting drugs such as reserpine (label): Additive blood-pressure lowering and marked slowing of the heart, which can cause vertigo, fainting or postural dizziness. (Source 7)
• Mirtogenol (bilberry extract plus Pycnogenol), an oral supplement (clinical trial): An 88-patient open supplement registry gave this combination alongside dorzolamide-timolol drops. Pressure and retinal microcirculation improved in all arms and the authors reported no side effects, so there is no signal of a harmful interaction. The design is a registry with no blinding or placebo, so it cannot show that the supplement adds anything. (Source 8)
• Other topical eye drops used at the same time (label): One drop can wash another out of the eye. The label requires at least five minutes between different ophthalmic drugs, and says two topical beta-blockers should not be used together. (Source 9)
• Alcohol (theoretical): We found no interaction study and no alcohol statement anywhere in this product's US label. The only documented basis for concern is indirect: timolol from the drop is absorbed systemically and hypotension is on the label's post-marketing list, so alcohol's own vasodilatory effect could in theory add to it. This is reasoning, not evidence. (Source 10)
• Food and ordinary meals (pharmacokinetic study): No food interaction is documented for an eye drop, and the label contains no food or meal instruction. The systemic dose from the eye is small: the label states plasma concentrations of dorzolamide are generally below the assay limit of quantitation, and this is the pharmacokinetic reason a food effect is not expected rather than a study showing none. (Source 11)

Stopping it

• No withdrawal syndrome, dependence or rebound phenomenon is described for this drop in the literature we reached, and the US label gives no tapering instruction. What the literature does record is that the drug's unwanted effects reverse when it is stopped: in four published cases of symptomatic bradycardia on timolol eye drops, heart rate returned to the normal range after discontinuation. (Source 12)
• Corneal toxicity attributed to the drop also reversed on stopping, in a case report after endothelial keratoplasty. (Source 13)
• The pressure-lowering effect is maintained only while the drop is used. The label records that the effect was consistent across 12 months of open-label continuation, which is evidence of sustained effect during treatment and not evidence about what happens after stopping; no randomised withdrawal trial of this product was found. (Source 14)
• Dorzolamide leaves the body very slowly because it binds inside red blood cells, so stopping the drop does not immediately clear the drug. A forensic case analysis in anti-doping testing describes a half-life of up to 150 days with incorporation into erythrocytes. (Source 15)

What goes wrong

In the same review, dorzolamide/timolol caused about twice as much eye irritation as brinzolamide/timolol but less blurred vision. (Source 16)

• Systematic review, Low certainty.
• Size: 12 studies (11 RCTs), 1,885 patients.
• Who: Glaucoma patients.
• How long: 4 weeks and longer.
• Result: Eye irritation risk ratio 0.51 for brinzolamide/timolol versus dorzolamide/timolol (i.e. 49% lower on brinzolamide/timolol), P < 0.001; blurred vision risk ratio 3.14, P < 0.001; high heterogeneity for overall adverse events.
• Funding: not stated in the abstract.

BT combination was associated with a 49% lower risk of eye irritation (RR = 0.51, P < 0.001) but a threefold higher risk of blurred vision (RR = 3.14, P < 0.001).

In the manufacturer's pooled trial experience, bitter taste or ocular stinging affected up to 30% of users and about 5% stopped the drug because of side effects. (Source 17)

• Official position, Certainty not rated.
• Size: Pooled trial population, size not given in this section.
• Who: People treated for open-angle glaucoma or ocular hypertension.
• How long: Up to 15 months.
• Result: Taste perversion or ocular burning/stinging up to 30%; conjunctival hyperaemia, blurred vision, superficial punctate keratitis or eye itching 5-15%; about 5% discontinued for adverse reactions. No placebo arm is reported in this section, so there is no drug-versus-placebo contrast here.
• Funding: manufacturer label (Thea Pharma Inc.), SPL published 2026-05-15.

The most frequently reported adverse reactions occurring in up to 30% of patients were taste perversion (bitter, sour, or unusual taste) or ocular burning and/or stinging.

Because dorzolamide is a sulfonamide absorbed systemically, the label records rare fatal sulfonamide reactions including Stevens-Johnson syndrome and aplastic anaemia. (Source 18)

• Official position, Certainty not rated.
• Size: Not quantified; spontaneous reports.
• Who: Users of topical dorzolamide-containing products.
• How long: Not stated.
• Result: No rate given; the label states fatalities have occurred rarely.
• Funding: manufacturer label (Thea Pharma Inc.), SPL published 2026-05-15.

Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias.

A self-controlled case-series in people hospitalised for bradycardia found the risk raised in the 31-180 days after starting ophthalmic timolol. (Source 19)

• Case series, Low certainty.
• Size: 6,373 patients hospitalised for bradycardia, of whom 267 were exposed to timolol.
• Who: Patients hospitalised for bradycardia who were at some point exposed to ophthalmic timolol.
• How long: Risk windows of 1-30, 31-180 and more than 180 days after initiation.
• Result: Incidence rate ratio 1.93 at 31-180 days. The abstract prints its confidence interval as 1.00-1.87, which is impossible; the paper's Results section and Table 2 give 95% CI 1.30-2.87. Other windows: 1.40 (0.87-2.26) in the first 30 days and 1.21 (0.64-2.31) beyond 180 days.
• Funding: not stated in the abstract.

Limit of this finding: The published abstract contains a printing error, and the quote reproduces it exactly: it reports the rate ratio as 1.93 but the confidence interval as 1.00-1.87, which cannot be right because 1.93 lies outside that range. The paper's own results section and Table 2 give the interval as 1.30-2.87. Read the risk estimate as 1.93 with a confidence interval of 1.30-2.87; do not treat 1.00-1.87 as a real range. This is also a self-controlled case-series, so it describes timing of risk within people who were hospitalised for bradycardia, not the chance of bradycardia for an average eye-drop user.

Risk of bradycardia was significantly increased in the 31-180 days after timolol initiation (incidence rate ratio (IRR) = 1.93; 95% confidence interval (CI) 1.00-1.87).

Four published cases of symptomatic bradycardia were attributed to timolol eye drops, with heart rate returning to normal after the drops were stopped. (Source 12)

• Case series, Very low certainty.
• Size: 4 cases.
• Who: People using timolol eye drops for primary open-angle glaucoma.
• How long: Not stated.
• Result: Heart rate returned to 60-100 beats per minute after discontinuation.
• Funding: not stated.

We present a series of four cases of symptomatic bradycardia resulting from the use of timolol eye drops and after discontinuation of the eye drops, heart rate improved to normal range (60-100 beats per minute).

A single case report describes acute corneal decompensation beginning the day dorzolamide/timolol was started after corneal endothelial transplant, reversing when the drop was stopped. (Source 13)

• Case report, Very low certainty.
• Size: 1 patient.
• Who: A 75-year-old woman two weeks after Descemet stripping automated endothelial keratoplasty.
• How long: Days.
• Result: Severe corneal oedema five days after starting the drop; gradual improvement and reduced corneal thickness after stopping.
• Funding: not stated.

On the day she started using the eye drops, the patient noticed an acute deterioration of visual acuity. Severe corneal edema was detected at follow-up 5 days later.

In a rabbit study where the diluted drops were injected into the front chamber of the eye, the corneal cell damage tracked the benzalkonium chloride preservative rather than the dorzolamide or the timolol. (Source 20)

• Animal study, Low certainty.
• Size: 22 rabbit eyes.
• Who: New Zealand white rabbits, diluted drops injected into the anterior chamber.
• How long: 24 hours.
• Result: Severe corneal oedema and endothelial apoptosis in the preserved group; mild oedema and minimal damage in the preservative-free group. This is an animal anterior-chamber injection model, not topical use in people.
• Funding: not stated in the abstract.

Limit of this finding: The design matters more than the conclusion here. The drops were diluted and injected directly into the rabbit's anterior chamber, which is not how eye drops are used; drops put on the surface of a healthy eye do not reach the inside of the eye at anything like that concentration. The study supports the narrower point that the preservative, not the two active drugs, was what damaged the cells in that model. It does not show that preserved dorzolamide/timolol drops damage the cornea in ordinary use, and the authors' closing line about preservative-free drops refers to the early period after eye surgery.

The main cause of corneal endothelial toxicity was due to the preservative in the dorzolamide/timolol fixed combination eyedrops, and not the active ingredient.

The label's post-marketing list for this product includes bradycardia, heart block, cardiac failure, respiratory failure, Stevens-Johnson syndrome and depression, with no estimable frequency. (Source 10)

• Official position, Certainty not rated.
• Size: Spontaneous reports from a population of uncertain size.
• Who: Users of COSOPT or COSOPT PF after approval.
• How long: Post-approval.
• Result: No rates can be estimated; causality is not established by these reports.
• Funding: manufacturer label (Thea Pharma Inc.), SPL published 2026-05-15.

bradycardia, cardiac failure, cerebral vascular accident, chest pain, choroidal detachment following filtration surgery, depression, diarrhea, dry mouth, dyspnea, heart block, hypotension, iridocyclitis, myocardial infarction, nasal congestion, Stevens-Johnson syndrome, toxic epidermal necrolysis, paresthesia, photophobia, respiratory failure, skin rashes, urolithiasis, and vomiting.

What the evidence supports

Across 114 randomised trials, timolol lowered intraocular pressure by about 3.7 mmHg and dorzolamide by about 2.5 mmHg at 3 months, placing both below the prostaglandin analogues. (Source 2)

• Meta-analysis, Moderate certainty.
• Size: 114 RCTs, 20,275 participants.
• Who: People with primary open-angle glaucoma or ocular hypertension.
• How long: 3 months.
• Result: Mean IOP reduction in mmHg (95% credible interval): bimatoprost 5.61 (4.94; 6.29), latanoprost 4.85 (4.24; 5.46), timolol 3.70 (3.16; 4.24), dorzolamide 2.49 (1.85; 3.13), brinzolamide 2.42 (1.62; 3.23)
• Funding: not stated in the abstract; the review was conducted by an academic group and searched the FDA website as well as trial databases.

timolol 3.70 (3.16; 4.24), brimonidine 3.59 (2.89; 4.29), carteolol 3.44 (2.42; 4.46), levobetaxolol 2.56 (1.52; 3.62), apraclonidine 2.52 (0.94; 4.11), dorzolamide 2.49 (1.85; 3.13)

The same trial concluded the fixed combination was as effective as its components, not better. (Source 21)

• Randomized trial, Low certainty.
• Size: 131 randomised.
• Who: Glaucoma patients in a national multicentre trial.
• How long: 1 month.
• Result: Equivalence rather than superiority.
• Funding: not stated.

The results of the randomized trial indicate that the fixed combination dorzolamide-timolol (Cosopt) was as effective as its components in controlling IOP, confirming results seen in phase 3 clinical trials.

Lowering intraocular pressure with topical medication in ocular hypertension roughly halved the 5-year rate of developing open-angle glaucoma, an absolute reduction of about 5 percentage points. (Source 3)

• Randomized trial, Moderate certainty.
• Size: 1,636 participants.
• Who: Adults aged 40-80 with ocular hypertension (IOP 24-32 mmHg in one eye) and no glaucomatous damage.
• How long: 60 months.
• Result: Cumulative probability of developing POAG 4.4% with medication versus 9.5% with observation; hazard ratio 0.40 (95% CI 0.27-0.59), P<.0001; absolute risk reduction about 5.1 percentage points, roughly 20 people treated for 5 years to prevent one conversion.
• Funding: not stated in the abstract; US multicentre trial.

At 60 months, the cumulative probability of developing POAG was 4.4% in the medication group and 9.5% in the observation group (hazard ratio, 0.40; 95% confidence interval, 0.27-0.59; P<.0001).

What the evidence does not support

In a randomised trial the fixed combination was no more effective than its two components given concomitantly, and the difference between them was not statistically significant. (Source 21)

• Randomized trial, Low certainty.
• Size: 131 randomised; plus a separate non-randomised replacement study of 404 patients.
• Who: Glaucoma patients already using a non-selective beta-blocker plus dorzolamide, after a 1-month run-in on the separate components.
• How long: 1 month after randomisation.
• Result: Percentage IOP change -3.2% at peak and -6.5% at trough for the fixed combination versus -0.3% and -3.2% for concomitant therapy; not statistically significant.
• Funding: not stated.

The percentage change in IOP was -3.2% at peak and -6.5% at trough for the combination and -0.3 and -3.2% for the concomitant group. These differences did not show statistical significance.

Dorzolamide given alone against its own vehicle for 5 years in ocular hypertension did not significantly reduce conversion to open-angle glaucoma. (Source 22)

• Randomized trial, Moderate certainty.
• Size: 1,081 patients at 18 European centres.
• Who: Patients aged 30 or over with ocular hypertension (IOP 22-29 mmHg), normal visual fields and normal optic discs, at moderate risk.
• How long: 60 months.
• Result: Cumulative probability of reaching an efficacy end point 13.4% with dorzolamide versus 14.1% with placebo; hazard ratio 0.86 (95% CI 0.58-1.26), P = 0.45.
• Funding: not stated in the abstract.

At 60 months, the cumulative probability of converting to an efficacy end point was 13.4% in the dorzolamide group and 14.1% in the placebo group (hazard ratio, 0.86; 95% confidence interval [CI], 0.58-1.26; P = 0.45).

Dorzolamide/timolol was no better and no worse than brimonidine plus timolol given separately over 6 months. (Source 23)

• Randomized trial, Low certainty.
• Size: 293 patients.
• Who: Ocular hypertension or primary open-angle glaucoma, after a 3-week timolol run-in.
• How long: 6 months.
• Result: Month 3, hour 2 adjusted mean IOP change -5.04 (SE 0.30) mmHg versus -5.41 (0.30) mmHg; treatment difference 0.36 (0.40) mmHg, 95% CI -0.42 to 1.14 mmHg, inside the prespecified +/-1.5 mmHg comparability margin.
• Funding: not stated in the abstract.

At month 3, hour 2, the dorzolamide/timolol group had an adjusted mean (standard error) change in IOP of -5.04 (0.30) mmHg versus -5.41 (0.30) mmHg in the brimonidine + timolol group, with a treatment difference of 0.36 (0.40) mmHg (95% confidence interval [CI] of -0.42-1.14 mmHg).

Where the evidence is mixed

The review that produced those estimates described its own included trials as of mixed risk of bias. (Source 2)

• Meta-analysis, Moderate certainty.
• Size: 114 RCTs, 20,275 participants.
• Who: People with primary open-angle glaucoma or ocular hypertension.
• How long: 3 months.
• Result: No pooled effect; a statement about study quality.
• Funding: not stated.

We included 114 RCTs with data from 20 275 participants. The overall risk of bias of the included trials is mixed.

The manufacturer's own label records that the fixed combination lowers pressure about 1 mmHg less than dorzolamide three times daily plus timolol twice daily given separately. (Source 14)

• Official position, Certainty not rated.
• Size: Clinical studies of 3 to 15 months duration; sizes not given in this section.
• Who: People with elevated intraocular pressure.
• How long: 3 to 15 months, with open-label extensions to 12 months.
• Result: Fixed combination greater than either monotherapy by 1-3 mmHg; about 1 mmHg less than concomitant dosing.
• Funding: manufacturer label (Thea Pharma Inc.), SPL published 2026-05-15.

The IOP-lowering effect of COSOPT twice daily was approximately 1 mmHg less than that of concomitant therapy with 2.0% dorzolamide three times daily and 0.5% timolol twice daily.

The authors of that negative trial attributed the null result partly to the vehicle group's own pressure fall, not to dorzolamide failing to lower pressure. (Source 22)

• Randomized trial, Moderate certainty.
• Size: 1,081 patients.
• Who: Ocular hypertension at moderate risk.
• How long: 60 months.
• Result: Dorzolamide lowered IOP 15% at 6 months and 22% at 5 years; placebo fell 9% at 6 months and 19% at 5 years.
• Funding: not stated.

the EGPS failed to detect a statistically significant difference between medical therapy and placebo in reducing the incidence of POAG among a large population of OHT patients at moderate risk for developing POAG, because placebo also significantly and consistently lowered IOP.

Brinzolamide/timolol lowered morning pressure slightly more than dorzolamide/timolol, but the reviewers judged the clinical relevance uncertain. (Source 16)

• Systematic review, Low certainty.
• Size: 12 studies (11 RCTs), 1,885 patients.
• Who: Glaucoma patients.
• How long: 4 to 12 or more weeks.
• Result: Morning IOP mean difference 0.56 mmHg favouring brinzolamide/timolol, P < 0.001; no significant difference in evening IOP.
• Funding: not stated in the abstract.

BT demonstrated a statistically greater reduction in the morning IOP compared to DT at 12 weeks or more (BT: MD = 0.56 mmHg, P < 0.001; BTFC subgroup: MD = 0.66, P < 0.001), with consistent benefits observed at 8 and 4 weeks.

Added to intravitreal bevacizumab for diabetic macular oedema, topical timolol-dorzolamide gave similar vision and similar macular thickness but a larger pressure fall. (Source 4)

• Meta-analysis, Very low certainty.
• Size: 4 RCTs, 98 patients (150 eyes)
• Who: Adults with diabetic macular oedema, mean age 57.9 years, 55.1% female.
• How long: Monthly injections with follow-up to 3 months in the component trials.
• Result: BCVA weighted mean difference -0.125 (95% CI -0.21 to -0.041); central macular thickness WMD -78.875 micrometres (95% CI -118.606 to -39.145); IOP WMD -1.244 mmHg (95% CI -2.548 to 0.06)
• Funding: not stated in the abstract.

Concurrent IVB with topical timolol-dorzolamide or dorzolamide alone demonstrated similar efficacy in improving BCVA and CMT in DME patients. However, the IVB+TD combination resulted in a more significant reduction in IOP compared to IVB alone.

Among retinitis pigmentosa patients whose macular oedema responded to topical dorzolamide, oedema recurred in nearly half within 5 years despite continued treatment. (Source 5)

• Cohort study, Very low certainty.
• Size: 40 patients who had responded to 1.0% topical dorzolamide.
• Who: Retinitis pigmentosa with cystoid macular oedema at one Japanese university hospital, retrospective.
• How long: Mean 3.9 years.
• Result: Recurrence 15.6% at 1 year, 34.7% at 3 years, 48.7% at 5 years; higher baseline central subfield thickness predicted recurrence (hazard ratio 1.11, 95% CI 1.05-1.18, P = 0.0004)
• Funding: not stated in the abstract.

During the mean 3.9-year follow-up, 14 patients exhibited recurrence; its rate was 15.6%, 34.7%, and 48.7% at 1, 3, and 5 years, respectively.

Where the research disagrees

Whether lowering intraocular pressure in people with ocular hypertension but no nerve damage prevents glaucoma

• Ocular Hypertension Treatment Study investigators (2002), Randomised trial of topical ocular hypotensive medication, any agent that reached a 20% pressure reduction target, versus observation, 1,636 participants: "At 60 months, the cumulative probability of developing POAG was 4.4% in the medication group and 9.5% in the observation group (hazard ratio, 0.40; 95% confidence interval, 0.27-0.59; P<.0001)." (Source 3)
• European Glaucoma Prevention Study investigators (2005), Randomised, double-masked trial of dorzolamide versus its vehicle, 1,081 patients, 5 years: "the EGPS failed to detect a statistically significant difference between medical therapy and placebo in reducing the incidence of POAG among a large population of OHT patients at moderate risk for developing POAG, because placebo also significantly and consistently lowered IOP." (Source 22)

Whether combining dorzolamide and timolol in one bottle is as strong as using the two drops separately

• Solish and colleagues, randomised arm (2004), Randomised controlled trial, 131 patients, 1 month: "The percentage change in IOP was -3.2% at peak and -6.5% at trough for the combination and -0.3 and -3.2% for the concomitant group. These differences did not show statistical significance." (Source 21)
• The product's US prescribing information, Regulatory position citing the 3-15 month registration studies; SPL published 2026-05-15: "The IOP-lowering effect of COSOPT twice daily was approximately 1 mmHg less than that of concomitant therapy with 2.0% dorzolamide three times daily and 0.5% timolol twice daily." (Source 14)

How much

• Reference intake: There is no dietary reference intake for a prescription eye drop. Dosing is set by the prescriber. As a position, the US label (SPL published 2026-05-15) states the dose is one drop in the affected eye or eyes twice daily, and that if more than one topical ophthalmic drug is used they should be given at least five minutes apart. (Source 9)
• Upper limit: No tolerable upper intake level exists for a prescription drug. The label sets no dose above twice daily and specifies that one single-use unit is used immediately after opening and the remainder discarded, which caps exposure per administration. Any higher frequency is outside the label. (Source 9)
• Studied: Registration programme: clinical studies of 3 to 15 months compared the fixed combination twice daily with 0.5% timolol twice daily and 2.0% dorzolamide twice and three times daily, with open-label extensions to 12 months. (Source 14)
• Studied: EGPS randomised 1,081 ocular hypertension patients to dorzolamide (the 2% topical formulation) or its vehicle for 5 years. (Source 22)
• Studied: The 114-trial network meta-analysis pooled single-agent topical regimens including timolol and dorzolamide at their standard commercial concentrations over 3 months. (Source 2)

A common belief, and what the research shows

The belief: Putting both drugs in one bottle makes the treatment stronger than using two separate bottles.

What the research shows: It does not. The convenience is the point, not extra potency. The product's own label states: "The IOP-lowering of COSOPT® administered twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol administered twice a day and 2% dorzolamide administered three times a day". A randomised trial reached the same conclusion from the other direction, reporting that "the fixed combination dorzolamide-timolol (Cosopt) was as effective as its components in controlling IOP, confirming results seen in phase 3 clinical trials." A second misconception is that eye drops stay in the eye: they do not, and the timolol in this drop is absorbed enough to be linked to hospitalisation for bradycardia.

Questions and answers

What is it?

It is a prescription eye drop holding two different pressure-lowering medicines in one bottle: dorzolamide hydrochloride 2%, which blocks an enzyme called carbonic anhydrase, and timolol maleate 0.5%, a beta-blocker of the same family as heart and blood-pressure tablets. It is sold with and without the preservative benzalkonium chloride. Its approved job is to lower pressure inside the eye in open-angle glaucoma or ocular hypertension when a beta-blocker alone has not reached the target. (Source 24)

What does it do in the body?

Both ingredients reduce how fast the eye manufactures aqueous humour, the fluid that fills the front of the eye, so less fluid goes in and the pressure falls. Dorzolamide does it by inhibiting carbonic anhydrase II in the ciliary body; timolol does it by blocking beta receptors in the same tissue. Neither one protects the optic nerve directly. High pressure is a risk factor for nerve damage, which is why pressure is the thing the drops target. (Source 1)

Is it good or bad for you?

It is useful in the specific situation it was made for and carries real risks outside it. In people whose eye pressure is high, pooled randomised evidence shows timolol lowers pressure by about 3.7 mmHg and dorzolamide by about 2.5 mmHg, less than the prostaglandin drops. Treating raised pressure in ocular hypertension halved the five-year rate of developing glaucoma in OHTS, from 9.5% to 4.4%. But the one large trial of dorzolamide against placebo did not show fewer conversions, and because the timolol is absorbed into the blood the drop is contraindicated in asthma, COPD, severe bradycardia and heart failure, and has been linked to hospitalisation for bradycardia. (Source 2)

How do you get more of it?

Not applicable in the sense the question usually means. This is a prescription medicine, not a nutrient, so there is no food, supplement or behaviour that raises your level of it, and the amount you get is entirely set by the prescribed drop schedule. The trials that define what is known used standard commercial concentrations given twice daily, compared against dorzolamide twice and three times daily and timolol twice daily. Dosing decisions belong to the prescriber. (Source 14)

If it is harmful, what reduces it?

Stopping the drop is what reduces exposure, and the medicine's unwanted effects have reversed on discontinuation in published cases of timolol-related bradycardia and of corneal swelling. One caveat: dorzolamide binds inside red blood cells and washes out slowly, with a reported half-life of up to 150 days, so blood levels do not vanish at once. There is no antidote and no literature on accelerating clearance. Stopping is a prescriber's decision because eye pressure will rise again. (Source 11)

Why might someone be low in it or missing it?

Does not apply. Nobody is naturally low in or deficient in a manufactured eye drop; you either have a prescription for it or you do not. The nearest real question is why someone might not get the pressure reduction the drop is supposed to deliver, and there the evidence points at tolerability rather than biology: bitter taste or stinging affects up to 30% of users and about 5% of people in the trials stopped the drug because of side effects, which is a route to under-treatment. (Source 17)

Which whole foods contain it or feed it?

None. There is no whole food that contains dorzolamide or timolol, and no food that feeds or substitutes for them; both are synthetic molecules made for pharmaceutical use. The only diet-related item documented anywhere in the product information is a theoretical caution about high-dose salicylate therapy, and even that concerns the oral drugs of this class rather than food. One supplement, an oral bilberry and Pycnogenol combination, has been given alongside the drops in an open registry with no reported side effects. (Source 8)

What happens if you do not have it?

Without the drop, untreated raised eye pressure carries a higher chance of developing glaucoma. In the OHTS trial, people with ocular hypertension who were only observed had a 9.5% chance of developing open-angle glaucoma over five years against 4.4% of those treated with pressure-lowering drops. That difference means about 20 people would need five years of treatment to prevent one conversion, and it is not specific to this drop: the trial allowed any topical agent that reached the pressure target. EGPS, which tested dorzolamide against placebo, did not reproduce a significant benefit. (Source 3)

How can you test for it?

What gets measured is the effect, not the drug: eye pressure by tonometry, visual fields and the appearance of the optic disc, which are exactly the end points the trials used. EGPS, for example, required a visual field change to be confirmed by two further positive tests and optic disc change to be agreed by two of three independent observers, which tells you how much confirmation these measures need to be reliable. Dorzolamide itself can be detected in urine and plasma by mass spectrometry, at concentrations of a few ng/mL in a documented anti-doping case, but that is forensic testing rather than clinical monitoring. (Source 22)

References

1. Thea Pharma Inc. via DailyMed (FDA label, SPL published 2026-05-15). COSOPT PF (dorzolamide hydrochloride and timolol maleate) ophthalmic solution - US prescribing information - Mechanism of Action 12.1 first paragraph. 2026. Read the source
2. Ophthalmology. Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.. 2016. PMID 26526633, DOI 10.1016/j.ophtha.2015.09.005. Read the source
3. Archives of ophthalmology (Chicago, Ill. : 1960). The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.. 2002. PMID 12049574, DOI 10.1001/archopht.120.6.701. Read the source
4. Clinical ophthalmology (Auckland, N.Z.). Intravitreal Bevacizumab Alone Vs Combined With Topical Timolol-Dorzolamide or Dorzolamide for Diabetic Macular Edema: A Systematic Review and Meta-Analysis.. 2025. PMID 40151418, DOI 10.2147/opth.s509136. Read the source
5. Retina (Philadelphia, Pa.). RECURRENCE RATE OF CYSTOID MACULAR EDEMA WITH TOPICAL DORZOLAMIDE TREATMENT AND ITS RISK FACTORS IN RETINITIS PIGMENTOSA.. 2022. PMID 34393209, DOI 10.1097/iae.0000000000003286. Read the source
6. Thea Pharma Inc. via DailyMed (FDA label, SPL published 2026-05-15). COSOPT PF (dorzolamide hydrochloride and timolol maleate) ophthalmic solution - US prescribing information - Drug Interactions 7.1-7.4. 2026. Read the source
7. Thea Pharma Inc. via DailyMed (FDA label, SPL published 2026-05-15). COSOPT PF (dorzolamide hydrochloride and timolol maleate) ophthalmic solution - US prescribing information - Drug Interactions 7.5-7.8. 2026. Read the source
8. European review for medical and pharmacological sciences. Mirtogenol® supplementation in association with dorzolamide-timolol or latanoprost improves the retinal microcirculation in asymptomatic patients with increased ocular pressure.. 2017. PMID 29131240. Read the source
9. Thea Pharma Inc. via DailyMed (FDA label, SPL version 2026-05-15). COSOPT PF (dorzolamide hydrochloride and timolol maleate) ophthalmic solution - US prescribing information - Full Prescribing Information, sections 2 Dosage and Administration and 3 Dosage Forms and Strengths. 2026. Read the source
10. Thea Pharma Inc. via DailyMed (FDA label, SPL version 2026-05-15). COSOPT PF (dorzolamide hydrochloride and timolol maleate) ophthalmic solution - US prescribing information - COSOPT PF label, Post-Marketing Experience. 2026. Read the source
11. Thea Pharma Inc. via DailyMed (FDA label, SPL published 2026-05-15). COSOPT PF (dorzolamide hydrochloride and timolol maleate) ophthalmic solution - US prescribing information - Pharmacokinetics 12.3. 2026. Read the source
12. Cureus. Ophthalmic Timolol and Hospitalization for Symptomatic Bradycardia and Syncope: A Case Series.. 2020. PMID 32292680, DOI 10.7759/cureus.7270. Read the source
13. Cornea. Reversible Corneal Decompensation Caused by a Topical Dorzolamide/Timolol Fixed Combination After Descemet Stripping Automated Endothelial Keratoplasty.. 2022. PMID 35942545, DOI 10.1097/ico.0000000000002894. Read the source
14. Thea Pharma Inc. via DailyMed (FDA label, SPL version 2026-05-15). COSOPT PF (dorzolamide hydrochloride and timolol maleate) ophthalmic solution - US prescribing information - COSOPT PF label, Clinical Studies. 2026. Read the source
15. Drug testing and analysis. Adverse analytical finding due to red blood cells transfusion: A rare case involving the diuretic dorzolamide.. 2022. PMID 35818742, DOI 10.1002/dta.3342. Read the source
16. European journal of ophthalmology. Comparative safety and efficacy of brinzolamide/timolol and dorzolamide/timolol in the treatment of glaucoma patients: A systematic review and meta-analysis.. 2026. PMID 41697795, DOI 10.1177/11206721261422832. Read the source
17. Thea Pharma Inc. via DailyMed (FDA label, SPL version 2026-05-15). COSOPT PF (dorzolamide hydrochloride and timolol maleate) ophthalmic solution - US prescribing information - COSOPT PF label, Adverse Reactions: Clinical Trials Experience. 2026. Read the source
18. Thea Pharma Inc. via DailyMed (FDA label, SPL version 2026-05-15). COSOPT PF (dorzolamide hydrochloride and timolol maleate) ophthalmic solution - US prescribing information - COSOPT PF label, Warnings: Sulfonamide Hypersensitivity. 2026. Read the source
19. Journal of ophthalmology. Association between Ophthalmic Timolol and Hospitalisation for Bradycardia.. 2015. PMID 25874117, DOI 10.1155/2015/567387. Read the source
20. Korean journal of ophthalmology : KJO. Kwon J, Heo JH, Kim HM, Song JS. Comparison of Cytotoxic Effects on Rabbit Corneal Endothelium between Preservative-free and Preservative-containing Dorzolamide/timolol. Korean Journal of Ophthalmology 2015;29(5):344-350. Cite as Kwon et al. 2015; Kim HM is the third author, so the key "kim-2015-bak-endothelium-rabbit" is a legacy key that implies the wrong first author.. 2015. PMID 26457041, DOI 10.3341/kjo.2015.29.5.344. Read the source
21. Journal of clinical pharmacy and therapeutics. Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol -- a randomized controlled trial and a replacement study.. 2004. PMID 15271105, DOI 10.1111/j.1365-2710.2004.00574.x. Read the source
22. Ophthalmology. Results of the European Glaucoma Prevention Study.. 2005. PMID 15745761, DOI 10.1016/j.ophtha.2004.11.030. Read the source
23. Ophthalmology. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.. 2003. PMID 12623832, DOI 10.1016/s0161-6420(02)01900-0. Read the source
24. Thea Pharma Inc. via DailyMed (FDA label, SPL version 2026-05-15). COSOPT PF (dorzolamide hydrochloride and timolol maleate) ophthalmic solution - US prescribing information - HIGHLIGHTS OF PRESCRIBING INFORMATION, Indications and Usage. 2026. Read the source